Abzena PLC 'Abzena inside' product enters Phase II trial
March 06 2017 - 1:01AM
RNS Non-Regulatory
TIDMABZA
Abzena PLC
06 March 2017
Abzena plc
'Abzena inside' product for neurodegenerative conditions
moves into Phase II trial
Cambridge, UK, 6 March 2017 - Abzena plc (AIM: ABZA, 'Abzena' or
the 'Group'), a life sciences group providing services and
technologies enabling the development and manufacture of
biopharmaceutical products, notes that one of the 'Abzena inside'
Composite Human Antibody(TM) products previously disclosed as being
in Phase I trials is moving forwards into a Phase II clinical
trial.
The product is being developed by an un-named major US
pharmaceutical company for the treatment of neurodegenerative
conditions and has been studied to date in two Phase I clinical
trials.
Dr John Burt, Abzena's CEO, said:
"We are pleased to see the progression of this 'Abzena inside'
product into Phase II clinical development following the recent
similar announcements about two other 'Abzena inside' products.
This illustrates the strength we have in the portfolio of products
that our partners are developing based on our antibody engineering
technology."
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer
Julian Smith, Chief Financial Officer +44 1223 903498
Instinctif Partners +44 20 7457 2020
Melanie-Toyne Sewell / Rozi Morris abzena@instinctif.com
/ Alex Shaw
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFELLBDXFZBBE
(END) Dow Jones Newswires
March 06, 2017 02:01 ET (07:01 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024